Hi, Yuxi: Provincial policy helps Walvax attract talents

Yunnan Walvax Biotechnology Co., Ltd. (Walvax) is a pharmaceutical enterprise, engaged in research and development, manufacturing and distribution of vaccines for humans.

Up to now, Walvax which assembled a core innovation team, has completed the development and marketing of 3 conjugate vaccines (5 descriptions), including 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), Group A and C meningococcal polysaccharide vaccine (MPV AC), and Haemophilus influenza type b conjugate vaccine (Hib).

Huang Zhen, vice chairman of Walvax, said: "Our company has received support from government at all levels in project construction, scientific research and development, talent placement and more. Walvax also constantly improves the level of scientific research to serve the society with better products."

When he came to Yunnan for career development at the beginning, Huang encountered a lot of difficulties and setbacks. Thank to the funding support of scientific and technological project at that time, he managed to lead the research and development of the products which have come to market later.

In recent years, central Yunnan’s Yuxi city has launched the evaluation and identification of high-end talents in Yunnan, selecting the first batch of 11 leading companies as the pilot sites.

Through the policy, the high-end talents who have been identified by the enterprise can benefit from the municipal talent introduction and cultivation policy. Walvax is one of the first pilot enterprises.

Source: Kunming Times; Photos by Yunnan Science and Technology Department; Trans-editing by Mo Yingyi